Publication: Adoptive cellular immunotherapy. NK cells and bone marrow transplantation
Loading...
Date
2000
Authors
Koh, C.Y. ; Welniak, L.A. ; Murphy, W.J.
item.page.secondaryauthor
item.page.director
Publisher
Murcia : F. Hernández
publication.page.editor
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Allogeneic bone marrow transplantation
(BMT) has been increasingly used for the treatment of
both neoplastic and non-neoplastic disorders. However,
serious obstacles currently limit the efficacy and thus
more extensive use of BMT. These obstacles include:
graft-versus-host disease (GVHD), relapse from the
original tumor, and susceptibility of patients to
opportunistic infections due to the immunosuppressive
effects of the conditioning regimen.Overcoming these
obstacles is complicated by dual outcome of existing
regimens; attempts to reduce GVHD by depleting T cells
from the graft, result in increased rates of tumor relapse
and failure of engraftment. On the other hand, efforts to
increase graft-versus-tumor (GVT) effects of the
transplant also promote GVHD. In this review, the use of
natural killer (NK) cells to overcome some of these
obstacles of allogeneic BMT is evaluated. Adoptive
immunotherapy using NK cells after allogeneic BMT
has several potential advantages. First, NK cells can
promote hematopoiesis and therefore engraftment by
production of hematopoietic growth factors. Second, NK
cells have been shown to prevent the incidence and
severity of GVHD. This has been shown to be at least
partially due to TGF-B, an immunosuppressive cytokine.
Third, NK cells have been shown to augment numerous
anti-tumor effects in animals after BMT suggesting a
vital role of NK cells in mediating GVT effects. Finally,
NK cells have been demonstrated to affect B cell
recovery and function in mice. Therefore, understanding
the mechanisms of beneficial effects of NK cells after
BMT may lead to significant increases in the efficacy of
this procedure.
Citation
item.page.embargo
Ir a Estadísticas
Sin licencia Creative Commons.